CureVac N.V. (NASDAQ:CVAC) to cut its workforce by 30% as part of a restructuring initiative, as GSK (NYSE:GSK) acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, for €1.45 billion plus royalties. The new agreement extends CureVac’s (CVAC) cash runway into 2028, asContinue Reading
AstraZeneca (NASDAQ:AZN) said Monday its marketing authorization application for its investigational COVID-19 prevention drug, sipavibart, has been accepted for an accelerated assessment by the EU drug regulator. The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use granted sipavibart accelerated assessment as it was deemed of major interestContinue Reading
MarsBars/E+ via Getty Images Novavax (NASDAQ:NVAX) has submitted an application to the European Medicines Agency seeking authorization of its JN.1 COVID-19 vaccine to be administered starting in the fall. The shot is also effective against the KP.2 and KP.3 variants, which alone account for nearly 54% of the cases currentlyContinue Reading
